Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

New research from University of Iowa dispels the belief that pharmaceutical mergers lead to higher drug prices, showing a decrease in prices for generic drugs.

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

LCCI Hyderabad will focus on scaling up Lilly’s innovation and efficiency by unlocking new technological advancements ...

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, Mounjaro and Zepbound, remains massive, their sales were hurt due to ...

The GCC, to be known as the Lilly Capability Centre India (LCCI), will be the company’s second centre in the country, ...

Good morning! Meta's elimination of fact-checking opens the door to misogynistic speech, Jane Fraser faces a test at Citi, ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

The company further said it plans to employ around 1,000 to 1,500 highly-skilled professionals including technology engineers ...

Lupin's Pithampur manufacturing unit produces both APIs (Active Pharmaceutical Ingredients) and finished products ...